|
|
10/18/2004 9:49:21 AM ET
DR. GUTMAN PRESENTS IN HOUSE O24 STUDY AT AARP NATIONAL EVENT FOR SWISS MEDICA’S 024 U.S.
CONSUMER DEBUT
FOR IMMEDIATE RELEASE
Stock Symbol: OTC BB: SWME
October 18, 2004
DR. GUTMAN PRESENTS IN HOUSE O24 STUDY AT AARP NATIONAL EVENT FOR SWISS MEDICA’S 024 U.S.
CONSUMER DEBUT
Toronto, Canada – Swiss Medica’s U.S. consumer debut for the Company’s O24™ Essential Oil Pain Neutralizer,
October 14-16, in Las Vegas at the AARP National Event was met with an enthusiastic response. Dr. E. Michael
Gutman, a double board-certified neuropsychiatric pain management specialist based in Orlando (Florida),
presented the findings of a recent in-house patient outcome study. Reportedly, more than 25,000 AARP
members and guests attended the Las Vegas national event, which featured presidential candidate John Kerry
and First Lady Laura Bush, as well as numerous celebrities.
Featured speaker, Dr. Gutman, announced to AARP members in a packed, standing-room-only, presentation
area, “O24 should be an integral part of everyone’s pain management strategy.” Dr. Gutman announced in his
clinic’s study that O24™ reduced pain by 73 percent in patients and that 86 percent benefited by four or more
hours of pain relief when using the O24™ Essential Oil Pain Neutralizer. In the study, O24™ was compared to
Ben Gay®, Bio Freeze®, Tiger Balm®, and other pain relief medications, including pain pills. O24™ was
preferred by an overwhelming percentage of patients who unanimously announced that O24™ was better than
other brands compared.
“We are astounded by the rapid and resounding acceptance of the O24™ pain relief product from our target
audience of the fifty-plus age group,” said Grant Johnson, Swiss Medica’s President and Chief Operating Officer.
“Our very high expectations going into the AARP National Event were quickly surpassed, as witnessed by the
robust demand for the Company’s product at our exhibit booth. That was reflected in very strong ongoing O24™
product sales, when at one point we were selling bottles at the rate of one every three minutes.”
About Swiss Medica Inc.
Swiss Medica commercializes proprietary bioscience products that relieve chronic ailments. We increase our
market share through focused distribution strategies in multiple sales channels. Swiss Medica’s mission is to be
a world leader in the commercialization of life enhancing bioscience products that improve quality of lives. Please
visit our websites at www.swissmedica.com and www.024zone.com
Swiss Medica’s flagship product, the 024™ Essential Oil Pain Neutralizer, holds US Patent #6,444,238B1. The
024™ pain relief solution has been used, recommended and praised for its fast-acting and long-lasting benefits
by healthcare professionals in the United States, Canada and in Europe. O24 is widely available throughout
Canada in leading pharmacies and natural food stores. It is available in the United States and elsewhere by
visiting www.024zone.com, for ordering details and store locators.
Forward-looking statements in this news release are made pursuant to the "Safe Harbor" provisions of the
United States Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking
statements involve risks and uncertainties, including, without limitation, risks relating to the ability to close
transactions being contemplated, risks related to international sales and potential foreign currency exchange
fluctuations, continued acceptance of Swiss Medica’s products, increased levels of competition, technological
changes, dependence on intellectual property rights and other risks detailed from time to time in Swiss Medica’s
periodic reports filed with the United States Securities and Exchange Commission and other regulatory
authorities.
Investor Relations Contact:
David Jones
Swiss Medica Inc.
1 866 485 4243
djones@swissmedica.com
|
|
